Exchange: NASDAQ·Updated 09:32 AM EST

UPB News

News
all
press releases
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -5.77% and +2.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -5.77% and +2.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage...
Yahoo! Finance: News
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alnylam (ALNY) delivered earnings and revenue surprises of +39.00% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Upstream Bio (NASDAQ:UPB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average rating of "Moderate Buy" by the five analysts that are covering the company, MarketBeat.com reports. One research analyst...
MarketBeat
Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two h...
MarketBeat
Wall Street Zen lowered shares of Upstream Bio from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat

Advertisement|Remove ads.